Catalyst Pharmaceuticals Announces Positive Topline Results from Phase 1 Vamorolone Study

Catalyst's Vamorolone Phase 1 Study Shows Favorable Corticosteroid Profile

Catalyst Pharmaceuticals, Inc. reported positive topline results from a two-part Phase 1 clinical study of vamorolone in healthy adult volunteers. The study demonstrated that vamorolone exhibits balanced corticosteroid activity, achieving expected cortisol suppression and anti-inflammatory effects without significant immunosuppressive activity at clinical doses. Part A compared vamorolone (300 mg) with deflazacort (0.9 mg/kg), showing comparable cortisol suppression and less pronounced immunosuppressive effects for vamorolone. Part B, an ascending dose evaluation (9, 27, 40 mg/kg/day), confirmed that clinically relevant immunosuppression only occurred at the highest, supratherapeutic dose. These findings support vamorolone's potential as a differentiated treatment for a broad range of chronic inflammatory rare diseases, offering glucocorticoid and anti-inflammatory benefits with a favorable immunosuppression profile.

• Equipotency and Differentiated Immunosuppression Profile: Part A of the Phase 1 study, involving 24 healthy adults, compared single doses of vamorolone (300 mg) and deflazacort (0.9 mg/kg). Both agents showed expected on-target glucocorticoid receptor activity, including similar cortisol suppression and leukocyte redistribution. Crucially, vamorolone demonstrated less pronounced immunosuppressive biomarker effects compared with deflazacort, supporting its currently labeled dosing for DMD and suggesting no need for dosing adjustments when switching patients.
• Dose-Dependent Immunosuppression at Supratherapeutic Levels: Part B of the study evaluated ascending doses of vamorolone (9, 27, or 40 mg/kg once daily for seven days) in 36 healthy volunteers. Clinically relevant immunosuppressive effects were observed only at the highest dose level (40 mg/kg/day), which is above currently approved dosing and higher than doses previously studied. Lower clinical doses (9 or 27 mg/kg/day) showed no relevant immunosuppressive effects, indicating a favorable safety profile at therapeutic levels.
• Potential for Broad Application in Chronic Inflammatory Rare Diseases: The overall findings suggest that vamorolone delivers robust glucocorticoid and anti-inflammatory activity without clinically meaningful immunosuppression at relevant doses. This balanced corticosteroid profile has the potential to distinguish vamorolone from conventional corticosteroids, supporting its utility across a broad range of chronic inflammatory rare diseases beyond its current indication for Duchenne Muscular Dystrophy (DMD).

Unpacking Vamorolone's Unique Glucocorticoid Activity and Safety Profile

Across its clinical development program in Duchenne muscular dystrophy (DMD), vamorolone has demonstrated a consistently favorable tolerability profile relative to standard corticosteroids. In the pivotal VISION-DMD trial—a randomized, double-blind, 24-week study in 121 boys with DMD (mean age 5.4 years)—vamorolone at doses up to 6.0 mg/kg/day was shown to be effective and safe, with height percentiles declining in prednisone-treated but not vamorolone-treated participants (change from baseline: prednisone −1.88 [8.81] vs. vamorolone 6 mg/kg/day +3.86 [6.16] percentile; P=0.02). Bone turnover markers declined with prednisone but remained stable with vamorolone. These findings were corroborated in a 30-month long-term extension study, in which vamorolone-treated boys maintained stable height percentiles (0.37 percentile/month; 95% CI, 0.23–0.52), with no statistically significant difference in BMI z-score change compared to matched historical glucocorticoid controls (0.002 vs. DNHS SD/month; 95% CI, −0.006 to 0.010; P=0.58). A subsequent 48-week crossover study further demonstrated rapid reversal of prednisone-induced declines in bone turnover biomarkers upon transition to vamorolone, and significant improvement in linear growth in the prednisone-to-vamorolone 6 mg/kg/day crossover group. The most recent 2026 cross-trial comparison confirmed that vamorolone 6 mg/kg/day achieved similar motor efficacy to prednisone 0.75 mg/kg/day and deflazacort 0.9 mg/kg/day at 12 months, while preserving linear growth (12-month LSM difference in height Z-scores: vamorolone vs. prednisone 0.57 [0.24–0.90]; vamorolone vs. deflazacort 0.72 [0.53–0.91]), though BMI Z-scores increased most with vamorolone.

Adrenal suppression represents the most consistently documented safety concern across vamorolone studies and affects patients in a dose-dependent manner. In the VISION-DMD trial, all three treatment arms—vamorolone 2 mg/kg/day, vamorolone 6 mg/kg/day, and prednisone—were associated with increased adrenal insufficiency, with boys at baseline already exhibiting low ACTH-stimulated cortisol. In the VBP15-006 study, morning serum cortisol reductions were observed in all patients and were more pronounced at 6 mg/kg/day. A clinical case report highlighted an episode of hyponatremia (119 mmol/L) and mild hyperkalemia in a vamorolone-treated patient during intercurrent illness, raising concern for an adrenal crisis with a mineralocorticoid deficiency phenotype—a pattern reflective of vamorolone's mineralocorticoid receptor (MR) antagonist activity. The LIONHEART study in healthy adult males confirmed vamorolone's MR antagonism, with maximum effect observed at 4–6 hours post-dose and detectable activity up to approximately 10 hours. At 20 mg/kg, vamorolone was well tolerated in this population and reversed fludrocortisone-induced sodium retention without evidence of decreased potassium excretion. Vamorolone-specific biomarker changes—including increases in renin, klotho, fetuin A, and fetuin B—were observed and are consistent with its MR antagonist mechanism.

Additional safety signals identified across the development program warrant monitoring. Preclinical data in mdx mice showed that vamorolone, unlike prednisolone and deflazacort, distributes into the central nervous system due to low P-glycoprotein substrate activity, and was associated with depression-like behavior, raising the potential for CNS adverse effects in clinical populations. At efficacious doses, vamorolone also shared some adverse effects with other corticosteroids, including reductions in endogenous corticosterone, elevations in glucose, and decreases in osteocalcin, although femur bone density reductions reached statistical significance only with prednisolone. In younger DMD patients (2–<4 years), data from VBP15-006 and the EAP Canada follow-up (median exposure approximately 2 years) showed mostly mild treatment-emergent adverse events—predominantly gastrointestinal disorders and infections—with stable growth trajectories, though 8 of 19 patients developed BMI and weight z-score changes exceeding 0.5, suggestive of excessive weight gain over time. Overall, network meta-analyses confirmed no statistically significant differences in BMI z-score among vamorolone, prednisone, and deflazacort, while consistently demonstrating vamorolone's growth-protective advantage over traditional corticosteroids.

Vamorolone's Edge: Addressing Immunosuppression in Chronic Inflammation

Investigational and emerging therapies across chronic inflammatory conditions demonstrate meaningful efficacy gains relative to standard-of-care comparators, though safety trade-offs and economic constraints remain important considerations. Published data spanning JAK inhibitors, biologics, immunomodulators, and herbal medicines collectively underscore both the promise and limitations of moving beyond conventional immunosuppression. Critically, while these agents can ameliorate or arrest chronic inflammation, none have demonstrated curative potential, and sustained use inherently amplifies adverse event risk.

Why a Differentiated Corticosteroid is Needed for Rare Diseases

Current treatment approaches for chronic inflammatory rare diseases remain constrained by a combination of pharmacological limitations, delayed diagnosis, and systemic healthcare inequities. These challenges collectively underscore the need for more targeted, better-tolerated, and accessible therapeutic strategies across both common and rare inflammatory conditions.

• Reliance on non-specific immunosuppression: Current treatments depend predominantly on non-specific immunosuppressive agents and supportive therapies that, while capable of dampening inflammation and compensating for organ dysfunction, require lifelong administration and carry significant adverse effect burdens. Adverse events, insufficient therapeutic responses, and disease relapses remain persistent challenges across virtually all chronic inflammatory diseases.

• Limitations of conventional and alternative anti-inflammatory agents: Conventional anti-inflammatory drugs are generally constrained by their adverse effect profiles, limiting both efficacy and long-term tolerability. Alternative approaches, including natural compound-based therapies such as polyphenols, are further restricted by poor solubility, instability, low bioavailability, variable pharmacokinetics, and a lack of dose standardization — collectively impeding clinical translation.

• Inability to predict treatment response: For conditions such as atopic dermatitis and psoriasis, treatment responses cannot be predicted, and validated biomarkers enabling individualized medication selection have yet to be developed, limiting the precision of therapeutic decision-making.

• Diagnostic delays driven by disease rarity and low awareness: Diagnosis of autoinflammatory diseases is frequently delayed due to their extreme rarity and low clinical awareness. Rare causes of chronic skin inflammation are often missed owing to inadequate diagnostic infrastructure, and genetic testing via massive parallel sequencing panels carries waiting periods of three to six months in most Central and Eastern European countries.

• Risk of irreversible organ damage from uncontrolled disease: Uncontrolled autoinflammatory disease may progress to secondary amyloidosis; timely, directed anti-inflammatory therapy is critical to preventing the evolution of end-organ damage.

• Healthcare system and access disparities: Global organizational differences in healthcare systems generate significant variability in the availability and funding of therapies, producing a gap between recommended and implemented practices — particularly for IL-1-mediated autoinflammatory diseases. Differences in licensing and reimbursement of IL-1 inhibitors (anakinra and canakinumab) across Central and Eastern European countries further compound access inequities.

• Absence of structured transitional care programs: In the majority of Central and Eastern European countries, no structured transition program exists for patients with autoinflammatory diseases, with transition typically initiated only at or beyond age 18 — representing a critical gap in continuity of care.

• Limited disease-specific diagnostic tools and specialized infrastructure: Availability of disease-specific laboratory assessments, such as S100 proteins, remains restricted in Central and Eastern Europe. More broadly, patients with rare diseases encounter significant barriers to accurate diagnosis and treatment access due to limited clinical expertise, uneven geographic distribution of specialized services, and insufficient infrastructure.

Vamorolone's Differentiated Profile: A New Era for Steroid Therapy

The recent positive topline results from vamorolone's Phase 1 study in healthy adults underscore its potential to significantly reshape the landscape of chronic inflammatory disease management. As a novel dissociative steroid, vamorolone is engineered to deliver potent anti-inflammatory benefits, akin to traditional glucocorticoids, but with a markedly improved safety profile. This is a critical distinction, as the long-term use of conventional steroids is often hampered by debilitating side effects such as growth impairment, bone fragility, and metabolic disturbances, severely impacting patient quality of life.

Vamorolone's mechanism involves high-affinity binding to the glucocorticoid receptor while also acting as a mineralocorticoid receptor antagonist, and it is resistant to metabolism by 11β-hydroxysteroid dehydrogenase type 1. This unique pharmacology allows it to retain anti-inflammatory efficacy, as demonstrated in preclinical models of asthma, multiple sclerosis, and polyarthritis, and clinically in Duchenne muscular dystrophy (DMD), where it has shown comparable motor function improvements to standard of care glucocorticoids with reduced adverse effects on growth and bone health.

However, the path forward is not without its considerations. While vamorolone mitigates many traditional steroid side effects, it still causes dose-dependent adrenal suppression, requiring careful clinical management and patient education, especially during periods of illness. Furthermore, preclinical data suggest its ability to cross the blood-brain barrier, raising the potential for central nervous system-related side effects. Its mineralocorticoid receptor antagonism, while contributing to its differentiated profile, also necessitates vigilance for electrolyte imbalances like hyponatremia, particularly in vulnerable patient populations or those on specific co-medications. Addressing these nuances through robust patient management strategies will be key to maximizing vamorolone's therapeutic potential across a broader spectrum of chronic inflammatory rare diseases, offering a much-needed alternative for long-term treatment.